To the full analysis
Nanobiotix stock: growth
NANO.PAGrowth only counts when it reaches the bottom line. That is why revenue, earnings and free cash flow for Nanobiotix S.A. stand side by side here: revenue growing faster than earnings is growth that was bought.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
24.6%
per year from 2011 to 2025, per share −2.5%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2011 | |
|---|---|---|---|
| Revenue | 258.6% | 22.1% | 24.6% |
| Revenue per share | 213.9% | 8.2% | −2.5% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2011 | $1.51M | −$5.81M | −$5.4M |
| 2012 | $82.17K | −$5.91M | −$4.19M |
| 2013 | $204.93K | −$9.03M | −$7.79M |
| 2014 | $3.07M | −$10.59M | −$10.56M |
| 2015 | $4.45M | −$18.84M | −$20.3M |
| 2016 | $6.01M | −$24.25M | −$20.7M |
| 2017 | $4.12M | −$28.97M | −$24.7M |
| 2018 | $3.86M | −$33.63M | −$29.25M |
| 2019 | $75.35K | −$56.42M | −$47.61M |
| 2020 | $55.41K | −$37.22M | −$31.41M |
| 2021 | $11.08K | −$52.08M | −$34.61M |
| 2022 | $5.29M | −$63.21M | −$42.23M |
| 2023 | $33.31M | −$43.99M | −$14.2M |
| 2024 | −$12.86M | −$75.5M | −$22.6M |
| 2025 | $32.85M | −$26.55M | −$37.64M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Oct 2013)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.